COVID-19

The continued exclusion of patients from these discussions, characterised by closed-shop secrecy, is inconsistent with the proper administration of a public health program. Joint presentations at the start and end of the process are not enough.

Novo Nordisk and Rural Doctors Foundation will work to reduce barriers to care through a two-year collaboration to expand the GPs4RuralDocs program into southern New South Wales.

Wesfarmers Health has launched Pulse Rewards, bringing its pharmacy, health, and beauty brands together under a single loyalty platform that rewards customers across a broader range of everyday health and wellbeing interactions.

The Department of Health, Disability and Ageing’s recent restructure could signal that officials increasingly view a program like the Pharmaceutical Benefits Scheme as two interlocking systems of financing and service delivery.

The company framed the result as a reset intended to restore sustainable growth. Investors backed the company with its share price rising by more than 15 per cent after the announcement.

If the promise of biosimilars is only savings for the government, rather than savings and wider access, what is the point from a patient perspective? The one-dimensional focus on savings is an obvious policy failure.

Our HTA institution has 'belled its own cat' on AI by invoking the importance of 'governance' frameworks. What governance frameworks apply to the current process? It is, of course, a defensive response because they probably fear losing control to AI's disruptive potential to HTA, as Uber did to taxis.

The Pharmacy Guild Foundation was established to invest in initiatives that improve access to medicines and healthcare services, build pharmacist capability, and strengthen support for underserved communities.

Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027.

Dimerix has taken over sponsorship of a United States investigational new drug application for DMX-652, giving the Australian biotechnology company direct control of clinical development plans for its newly acquired acute kidney injury asset.

OncoSil Medical has received US Food and Drug Administration approval for its OncoSil device to treat patients with unresectable, non-metastatic distal cholangiocarcinoma, giving the Australian medical-device company a pathway into the world’s largest healthcare market.

The reforms aim to shift Pharmac toward a more responsive, transparent model, with greater emphasis on timely assessments, patient engagement, broader societal benefits, and closer coordination with Health New Zealand.